Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.

Clinical lung cancer - 1 Sept 2015

Park Sojung, Park Tai Sun, Choi Chang-Min, Lee Dae Ho, Kim Sang-We, Lee Jung-Shin, Kim Woo Sung, Song Joon Seon, Lee Jae Cheol

Abstract excerpt

BACKGROUND: There have been conflicting findings regarding the efficacy of pemetrexed for lung cancer with anaplastic lymphoma kinase (ALK) rearrangement. This study was conducted to explore the benefits of pemetrexed in this patient group. PATIENTS AND METHODS: Among patients who had received pemetrexed therapy between January 2010 and March 2014 for advanced stage lung adenocarcinoma, cases were selected with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Disease-Free Survival

Share to Gene Rearrangement

Share to Pemetrexed

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 25682546
DOI: 10.1016/j.cllc.2015.01.003

Genes

ALK
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.PMID 25682546Read ↗

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.Semantic proximity Read ↗

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.Semantic proximity Read ↗

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis.Semantic proximity Read ↗

Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.Semantic proximity Read ↗

Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.Semantic proximity Read ↗

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.Semantic proximity Read ↗

[Clinicopathological features of lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements].Semantic proximity Read ↗

Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database.Semantic proximity Read ↗

Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.Semantic proximity Read ↗

Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.